Intravenous dihydroergotamine for inpatient management of refractory primary headaches

Neurology

Volumn 77, Issue 20, 2011, Pages 1827-1832

  Nagy, Abraham J ^a,b   Gandhi, Sonia ^a,c   Bhola, Ria ^a,d   Goadsby, Peter J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Nevada Headache institute   (United States)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DIHYDROERGOTAMINE;

ABDOMINAL CRAMP; ADULT; ARTICLE; BURNING SENSATION; CHEST TIGHTNESS; CLUSTER HEADACHE; CONSTIPATION; DIARRHEA; DIZZINESS; DRUG WITHDRAWAL; DYSPNEA; ELECTROCARDIOGRAM; EYE PAIN; FEMALE; FOLLOW UP; HEADACHE; HOSPITAL PATIENT; HUMAN; INSOMNIA; INTERVIEW; LEG CRAMP; LIMB PAIN; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEW DAILY PERSISTENT HEADACHE; PRIMARY HEADACHE; PRIORITY JOURNAL; SIDE EFFECT; SWEETNESS; TRANSFORMED MIGRAINE;

EID: 82955243886     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3182377dbb     Document Type: Article

References (40)

1. Headache Classification Committee of The International Headache Society. The International Classification of Headache Disorders (second edition). Cephalalgia 2004;24:1-160.
2. Goadsby PJ, Lipton RB, Ferrari MD. Migraine: Current understanding and treatment. N Engl J Med 2002;346: 257-270.
3. Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: Data from the American Migraine Study II. Headache 2001;41:646-657. (Pubitemid 32777747)
4. Raskin NH. Repetitive intravenous dihydroergotamine as therapy for intractable migraine. Neurology 1986;36:995-997. (Pubitemid 16098249)
5. Berde B, Schild HO. Ergot Alkaloids and Related Compounds. Berlin: Springer-Verlag; 1978.
6. Horton BT, Peters GA, Blumenthal LS. A new product in the treatment of migraine: A preliminary report. Proc Staff Meet Mayo Clin 1945;20:241-248.
7. Pollock LA. Dihydroergotamine (D.H.E. 45), a new and effective drug in the treatment of migraine. Rocky Mt Med J 1946;43:895-897.
8. Kanto J, Allonen H, Koski K, et al. Pharmacokinetics of dihydroergotamine in healthy volunteers and in neurological patients after a single intravenous injection. Int J Clin Pharmacol Ther Toxicol 1981;19:127-130. (Pubitemid 11153018)
9. Little PJ, Jennings GL, Skews H, Bobik A. Bioavailability of dihydroergotamine in man. Br J Pharmacol 1982;13: 785-790. (Pubitemid 13139859)
10. Callaham M, Raskin N. A controlled study of dihydroergotamine in the treatment of acute migraine headache. Headache 1986;26:168-171. (Pubitemid 17199220)
11. Olesen J, Bousser MG, Diener HC, et al. New appendix criteria open for a broader concept of chronic migraine. Cephalalgia 2006;26:742-746.
12. Silberstein SD, Silberstein JR. Chronic daily headache: Long-term prognosis following inpatient treatment with repetitive IV DHE. Headache 1992;32:439-445.
13. Silberstein SD, Schulman EA, Hopkins MM. Repetitive intravenous DHE in the treatment of refractory headache. Headache 1990;30:334-339. (Pubitemid 20361182)
14. Silberstein SD, Young WB. Safety and efficacy of ergotamine tartrate and dihydroergotamine in the treatment of migraine and status migrainosus. Neurology 1995;45: 577-584.
15. Goadsby PJ, Gundlach AL. Localization of 3Hdihydroergotamine binding sites in the cat central nervous system: Relevance to migraine. Ann Neurol 1991;29: 91-94.
16. Hoskin KL, Kaube H, Goadsby PJ. Central activation of the trigeminovascular pathway in the cat is inhibited by dihydroergotamine: A c-Fos and electrophysiology study. Brain 1996;119:249-256.
17. Silberstein SD, Olesen J, Bousser MG, et al. The International Classification of Headache Disorders, 2nd edition (ICHD-II): Revision of criteria for 8.2 Medication- overuse headache. Cephalalgia 2005;25:460-465. (Pubitemid 40769867)
18. Goadsby PJ. New daily persistent headache: A syndrome not a discrete disorder. Headache 2011;41:650-653.
19. Welch KMA, Goadsby PJ. Chronic daily headache: Nosology and pathophysiology. Curr Opin Neurol 2002;15: 287-295. (Pubitemid 34596892)
20. Cohen AS, Matharu MS, Goadsby PJ. Short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing (SUNCT) or cranial autonomic features (SUNA): A prospective clinical study of SUNCT and SUNA. Brain 2006;129:2746-2760. (Pubitemid 44522107)
21. Cittadini E, Matharu MS, Goadsby PJ. Paroxysmal hemicrania: A prospective clinical study of thirty-one cases. Brain 2008;131:1142-1155. (Pubitemid 351499421)
22. Cittadini E, Goadsby PJ. Hemicrania continua: A clinical study of 39 patients with diagnostic implications. Brain 2010;133:1973-1986.
23. Goadsby PJ, Schoenen J, Ferrari MD, Silberstein SD, Dodick D. Towards a definition of intractable headache for use in clinical practice and trials. Cephalalgia 2006;26: 1168-1170. (Pubitemid 44199414)
24. Magnoux E, Zlotnik G. Outpatient intravenous dihydroergotamine for refractory cluster headache. Headache 2004;44:249-255. (Pubitemid 38436688)
25. Müller-Schweinitzer E. In vitro studies on the duration of action of dihydroergotamine. Int J Clin Pharmacol Ther Toxicol 1980;18:88-91. (Pubitemid 10169024)
26. Hamblin MW, Ariani K, Adriaenssens PI, Ciaranello RD. [3H]Dihydroergotamine as a high-affinity, slowly dissociating radioligand for 5-HT1b binding sites in rat brain membranes: Evidence for guanine nucleotide regulation of agonist affinity states. J Pharmacol Exp Ther 1987;243: 989-1001. (Pubitemid 18017152)
27. Eadie MJ. Ergotamine pharmacokinetics in man: An editorial. Cephalalgia 1983;3:135-138. (Pubitemid 14204150)
28. Jauslin P, Goadsby PJ, Lance JW. The hospital management of severe migrainous headache. Headache 1991;31: 658-660.
29. Burstein R, Jakubowski M, Levy D. Anti-migraine action of triptans is preceded by transient aggravation of headache caused by activation of meningeal nociceptors. Pain 2005; 115:21-28. (Pubitemid 40514451)
30. Leniger T, Pageler L, Stude P, Diener HC, Limmroth V. Comparison of intravenous valproate with intravenous lysine-acetylsalicylic acid in acute migraine attacks. Headache 2005;45:42-46. (Pubitemid 40096179)
31. Edwards KR, Norton J, Behnke M. Comparison of intravenous valproate versus intramuscular dihydroergotamine and metoclopramide for acute treatment of migraine headache. Headache 2001;41:976-980. (Pubitemid 34008133)
32. Saadah HA. Abortive migraine therapy in the office with dexamethasone and prochlorperazine. Headache 1994;34: 366-370. (Pubitemid 24217825)
33. Fiesseler FW, Shih R, Szucs P, et al. Steroids for migraine headaches: A randomized double-blind, two-armed, placebo-controlled trial. J Emerg Med 2011;40:463-468.
34. Friedman BW, Greenwald P, Bania TC, et al. Randomized trial of IV dexamethasone for acute migraine in the emergency department. Neurology 2007;69:2038-2044. (Pubitemid 350175705)
35. Couturier EGM, Hering R, Foster CA, Steiner TJ, Rose FC. First clinical study of selective 5-HT3 antagonist, granisetron (BRL 43694), in the acute treatment of migraine headache. Headache 1991;31:296-297.
36. Ferrari MD, Wilkinson M, Hirt D, Lataste X, Notter M. Efficacy of ICS 205-930, a novel 5-hydroxytryptamine3 (5-HT3) receptor antagonist, in the prevention of migraine attacks: A complex answer to a simple question: ICS 205-930 Migraine Study Group. Pain 1991;45:283-291.
37. Ziegler D, Ford R, Kriegler J, et al. Dihydroergotamine nasal spray for the acute treatment of migraine. Neurology 1994;44:447-453. (Pubitemid 24098143)
38. Aurora SK, Silberstein SD, Kori SH, et al. MAP0004, orally inhaled DHE: A randomized, controlled study in the acute treatment of migraine. Headache 2011;51:507-517.
39. Winner P, Ricalde O, Force BL, Saper J, Margul B. A double-blind study of subcutaneous dihydroergotamine vs subcutaneous sumatriptan in the treatment of acute migraine. Arch Neurol 1996;53:180-184. (Pubitemid 26055266)
40. Lipton RB, Stewart WF, Sawyer J, Edmeads JG. Clinical utility of an instrument assessing migraine disability: The Migraine Disability Assessment (MIDAS) questionnaire. Headache 2001;41:854-861. (Pubitemid 33043148)